This novel, best-in-class orally bioavailable proteosome inhibitor is being developed for the treatment of multiple myeloma and other cancers.
Employees: 11-50
Total raised: $1M
Founded date: 2004
Investors 3
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Avoro Capi... | avorocapit... |
| - | Fight Agai... | facit.ca |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.05.2011 | - | $1M | - |
Mentions in press and media 21
| Date | Title | Description |
| 29.10.2021 | Trillium Therapeutics Receives Final Court Order Approving Arrangement | CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is please... |
| 29.10.2021 | Trillium Therapeutics Receives Final Court Order Approving Arrangement - Form 8-K | Trillium Therapeutics Receives Final Court Order Approving Arrangement CAMBRIDGE, MA, October 28, 2021 Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company... |
| 28.10.2021 | Trillium Therapeutics Receives Final Court Order Approving Arrangement | CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is please... |
| 27.10.2021 | Trillium Securityholders Approve Acquisition by Pfizer - Form 8-K | Trillium Securityholders Approve Acquisition by Pfizer CAMBRIDGE, MA, October 26, 2021 / GlobeNewsWire / Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) ("Trillium" or the "Company") today announced that its securityholder... |
| 26.10.2021 | Trillium Securityholders Approve Acquisition by Pfizer | CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today ann... |
| 24.08.2021 | Why the end of Katerra doesn’t mean the end of construction tech investing | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. The high profile death of Katerra, a construction tech startup that aimed to slice and dice the c... |
| 24.08.2021 | Why the end of Katerra doesn’t mean the end of construction tech investing | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Takeda’s CEO on taking the Fortune Global 500 company into the future From Takeda Th... |
| 23.08.2021 | Pfizer : Event Announcement (PDF 263 KB) (opens in new window) | For Immediate Release August 23, 2021 Pfizer to Acquire Trillium Therapeutics Inc. Proposed acquisition strengthens Pfizer's category leadership in Oncology with addition of next- generation, investigational immuno-therapeutics for hematolo... |
| 23.08.2021 | Pfizer to buy cancer drug maker Trillium for $2.3B | More On: pfizer Pfizer: Booster raises Omicron antibodies for children 5-11 FDA authorizes second COVID-19 booster shots for adults 50 and up Kid-friendly: Moderna says its COVID vax safe for children under 6 Pfizer CEO says fourth COVID-19... |
| 23.08.2021 | Pfizer to buy Canadian cancer biotech company Trillium Therapeutics for $2.3 billion | Pharmaceutical giant Pfizer announced on Monday it has agreed to buy Canadian drug developer Trillium Therapeutics in a deal valued at $2.26 billion to strengthen its arsenal of blood cancer therapies. According to the announcement, Pfizer ... |
Show more